Stemgent Starts Scottish Protein Tools Venture

Mar 03, 2010

NEW YORK (GenomeWeb News) – Stem cell products developer Stemgent said today that it has started a new business in Scotland that will develop reagents and kits and offer services for use in studying the ubiquitin proteasome pathway (UPP) for drug research.

Stemgent, which has operations in Boston and San Diego, will invest roughly $4.5 million over three years in the new venture, which is based in Dundee.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

DNA Defense Not Convincing

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Keep on Brushing

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Panda Gut Seasonality

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

This Week in PLOS

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.

Featured White Papers

Lipid Removal With Reference Applications in Serum and Bile Proteomics

Albumin & IgG Removal Reference Applications

95-plex Immune Cell Phenotyping Assay

Oct

10

Featured Webinar

GenomeWeb/ABRF 2017 Webinar Series: Ask the Experts: Ensuring High-Quality Proteomic Studies with Core Lab Resources

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.

Main menu